Stockscreener 앱 받기
22.88
2.10%
-0.49
시장 영업 전:
22.58
-0.30
-1.31%
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News
Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com South Africa
Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com Australia
New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa
William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World
(NAMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha
NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks
7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga
Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India
Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks
NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com
Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times
NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey
10 Oversold Biotech Stocks to Buy Now - Insider Monkey
How to Take Advantage of moves in (NAMSW) - Stock Traders Daily
Newamsterdam pharma COO sells shares worth $1.8 million - Investing.com India
Newamsterdam pharma COO sells shares worth $1.8 million By Investing.com - Investing.com Nigeria
How To Trade (NAMS) - Stock Traders Daily
Mirae Asset Global Investments Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
abrdn plc Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Newamsterdam pharma CFO sells shares worth $1.5 million - MSN
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Where are the Opportunities in (NAMS) - Stock Traders Daily
Make Informed Decisions with NewAmsterdam Pharma Company NV (NAMS) Stock Updates - The News Heater
Ratios Uncovered: Breaking Down NewAmsterdam Pharma Company NV (NAMS)’s Trailing Twelve Months Metrics - The Dwinnex
NAMS: Strategic Executive Compensation Plan Unveiled138K Shares at $21.36 - StockTitan
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL
Results from NewAmsterdam Pharma Company NV (NAMS) show risk - US Post News
China Universal Asset Management Co. Ltd. Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
H.C. Wainwright initates NewAmsterdam Pharma Company NV (NAMS) rating to a Buy - Knox Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1%Still a Buy? - MarketBeat
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
JPMorgan Chase & Co. Increases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
How To Trade (NAMSW) - Stock Traders Daily
2.14%
2.83%
자본화:
|
볼륨(24시간):